The history of leptin in obesity treatment is a compelling narrative of scientific promise and clinical reality. Since its discovery in 1994, leptin—a hormone produced by fat tissue that signals energy stores to the brain—has transformed our understanding of weight regulation. Initial excitement about leptin as a potential obesity cure gave way to the recognition of 'leptin resistance', whereby the body fails to respond to the hormone's signals in common obesity. Today, leptin therapy occupies a highly specialised niche in UK clinical practice, licensed only for rare lipodystrophy syndromes rather than typical obesity. This article explores leptin's journey from breakthrough discovery to its current limited therapeutic role.

Discovery of Leptin and Its Role in Obesity

The discovery of leptin in 1994 by Jeffrey Friedman and colleagues at Rockefeller University represented a watershed moment in obesity research. This 16-kDa protein hormone, encoded by the ob gene and secreted primarily by white adipose tissue, was identified through studies of genetically obese mice. The name 'leptin' derives from the Greek word leptos, meaning thin, reflecting initial optimism about its therapeutic potential.

Leptin functions as a crucial adiposity signal in the hypothalamic regulation of energy homeostasis. It crosses the blood-brain barrier and binds to leptin receptors (particularly the long form, LepRb) in the arcuate nucleus of the hypothalamus. This binding activates the JAK-STAT signalling pathway, leading to:

• Suppression of orexigenic (appetite-stimulating) neuropeptides such as neuropeptide Y (NPY) and agouti-related peptide (AgRP)

• Activation of anorexigenic (appetite-suppressing) pathways involving pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART)

• Modulation of neuroendocrine function, including reproductive and thyroid axes

• Effects on energy expenditure, which are well established in rodent models but less pronounced and inconsistent in humans

In individuals with normal leptin signalling, circulating leptin concentrations correlate with adipose tissue mass, providing the brain with information about energy stores. When fat stores increase, leptin levels rise, theoretically triggering compensatory reductions in appetite. Conversely, during caloric restriction and weight loss, falling leptin levels signal energy deficit, promoting hunger and metabolic adaptation. This elegant system suggested leptin might be a key satiety hormone and sparked considerable excitement about its potential as a treatment for obesity.

In simpler terms: Leptin is a hormone made by fat tissue that tells the brain how much energy is stored in the body. When leptin works properly, it helps regulate appetite and weight. Scientists initially hoped it could be used as a medicine to treat obesity.

Early Clinical Trials of Leptin for Weight Management

Following leptin's discovery, pharmaceutical companies rapidly initiated clinical trials, anticipating a breakthrough obesity therapy. Initial studies focused on individuals with congenital leptin deficiency, an extremely rare autosomal recessive condition caused by mutations in the LEP gene. These patients present with severe early-onset obesity, hyperphagia, and hypogonadotropic hypogonadism. Leptin replacement therapy in these individuals produced dramatic results, with substantial weight loss, normalisation of eating behaviour, and restoration of reproductive function. These cases provided proof-of-concept that leptin could effectively regulate body weight when deficiency was the underlying cause.

Encouraged by these findings, researchers conducted trials in common obesity, where leptin deficiency is not the primary problem. Studies examined recombinant methionyl human leptin (r-metHuLeptin, later developed as metreleptin) administered by daily subcutaneous injection in dose-ranging trials. The results were disappointing: whilst some weight loss occurred in the highest dose groups, the magnitude was modest and not clinically significant for most participants. Subsequent larger trials confirmed these underwhelming results, with leptin monotherapy producing only marginal weight reduction compared to placebo.

Adverse effects included injection site reactions, which were commonly reported, alongside occasional nausea and headache. Development programmes were discontinued as it became clear that leptin administration alone would not provide the anticipated solution for common obesity. By the early 2000s, researchers began investigating the underlying mechanisms of this therapeutic failure, shifting focus towards understanding why the body does not respond to leptin in typical obesity.

Why Leptin Therapy Failed in Common Obesity

The failure of leptin therapy in common obesity stems from a phenomenon termed 'leptin resistance', whereby the brain becomes less responsive to leptin's signals despite elevated circulating concentrations. Most individuals with obesity have high leptin levels proportional to their increased adipose tissue mass, yet this fails to suppress appetite or increase energy expenditure as expected. This paradox represents a fundamental challenge to leptin-based therapeutics.

Several mechanisms are hypothesised to contribute to leptin resistance, with strongest evidence from animal models and mixed translational evidence in humans:

• Impaired blood-brain barrier transport: Saturatable transport systems may become overwhelmed at high leptin concentrations, reducing central nervous system exposure

• Receptor downregulation: Chronic hyperleptinemia may decrease leptin receptor expression or sensitivity in hypothalamic neurones

• Intracellular signalling defects: Activation of suppressor of cytokine signalling 3 (SOCS3) and protein tyrosine phosphatase 1B (PTP1B) inhibits leptin receptor signalling pathways

• Endoplasmic reticulum stress: Obesity-associated cellular stress may impair leptin signal transduction

• Inflammatory pathways: Chronic low-grade inflammation in obesity may activate pathways that interfere with leptin signalling

Additionally, the body's powerful homeostatic mechanisms resist sustained weight loss. When leptin levels fall during caloric restriction, compensatory increases in hunger and reductions in metabolic rate occur—responses that promote weight regain. Research has shown that administering leptin during weight-loss maintenance can partially reverse some of these adaptive responses, though this remains an investigational approach. This understanding fundamentally shifted the therapeutic paradigm, moving focus from leptin supplementation towards addressing leptin resistance or using leptin in specific clinical contexts where absolute deficiency exists.

Current Status of Leptin in UK Obesity Treatment

Within the UK healthcare system, leptin therapy occupies a highly specialised niche and is not indicated for common obesity. Metreleptin (recombinant human leptin analogue, brand name Myalepta) received European Medicines Agency (EMA) authorisation in 2018 for treating complications of leptin deficiency in lipodystrophy syndromes. The licensed indication is for generalised lipodystrophy (GL) in adults and children aged 2 years and above, and for partial lipodystrophy (PL) in adults and children aged 12 years and above, when standard treatments have not achieved adequate metabolic control. Lipodystrophy syndromes are rare conditions characterised by generalised or partial loss of adipose tissue, resulting in absolute leptin deficiency and severe metabolic complications including insulin resistance, hypertriglyceridaemia, and hepatic steatosis.

Metreleptin is not licensed for congenital leptin deficiency caused by LEP gene mutations, nor for leptin resistance or common obesity. Access to metreleptin for the exceptionally rare cases of congenital leptin deficiency requires specialist endocrinology assessment at tertiary metabolic centres and is arranged through NHS England specialised commissioning pathways or, in exceptional circumstances, individual funding requests for off-label use with genetic confirmation of LEP gene mutations.

Important safety information from the MHRA Summary of Product Characteristics (SmPC) includes:

• Risk of developing neutralising anti-metreleptin antibodies, which may lead to severe infections, loss of efficacy, or loss of endogenous leptin activity

• Cases of T-cell lymphoma have been reported in patients with acquired GL treated with metreleptin

• Hypoglycaemia may occur, particularly in patients with diabetes; insulin or insulin secretagogue doses must be adjusted and blood glucose monitored closely

• Injection site reactions are common

• Autoimmunity and hypersensitivity reactions have been reported

If you experience any side effects, talk to your doctor or pharmacist. You can also report suspected side effects directly via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by downloading the Yellow Card app.

The NICE guidance framework does not include leptin therapy for common obesity management. Current NICE-recommended pharmacological interventions for obesity include:

• Orlistat (lipase inhibitor) for adults meeting specific BMI and comorbidity criteria (NICE CG189)

• Semaglutide 2.4 mg (GLP-1 receptor agonist) for weight management in adults with at least one weight-related comorbidity and a BMI ≥35 kg/m² (or ≥32.5 kg/m² for some minority ethnic groups), or BMI ≥30 kg/m² (or ≥27.5 kg/m² for some groups) with specific conditions (NICE TA875)

• Liraglutide 3 mg may be available in some areas, though commissioning varies locally

These agents work through different mechanisms—reducing fat absorption or enhancing satiety through incretin pathways—and have demonstrated clinically meaningful weight loss in large trials.

Patients enquiring about leptin treatment should be counselled about evidence-based alternatives available through NHS pathways, including:

• Tier 1–2 services: Lifestyle interventions with dietary advice, physical activity support, and behavioural change programmes

• Tier 3 services: Specialist multidisciplinary weight management services

• Tier 4 services: Bariatric (weight loss) surgery for eligible individuals meeting NICE criteria (typically BMI ≥40 kg/m², or ≥35 kg/m² with significant comorbidities; lower thresholds apply for some minority ethnic groups and for recent-onset type 2 diabetes)

For further information on NHS weight management services, visit www.nhs.uk/live-well/healthy-weight or speak with your GP.

Future Directions: Leptin Sensitisers and Combination Therapies

Contemporary obesity research has pivoted towards strategies that enhance leptin sensitivity or exploit leptin's physiological roles in novel therapeutic combinations. It is important to emphasise that no leptin-based therapies are MHRA-approved for common obesity, and the approaches described below remain investigational.

Leptin sensitisers—agents that restore or enhance leptin receptor signalling—represent an active area of preclinical and early clinical investigation. Several targets have been identified, primarily in animal models:

• PTP1B inhibitors: Protein tyrosine phosphatase 1B negatively regulates leptin signalling; its inhibition enhances leptin sensitivity in rodent models, though human translation remains uncertain

• SOCS3 antagonists: Blocking suppressor of cytokine signalling 3 may restore leptin receptor function in preclinical studies

• Celastrol: This natural compound derived from Tripterygium wilfordii demonstrated anti-obesity effects in mice, apparently by improving leptin sensitivity. However, human data are lacking and safety concerns (including potential toxicity) have been raised

• Anti-inflammatory agents: Targeting obesity-associated inflammation may indirectly improve leptin signalling, though evidence in humans is limited

Combination therapy approaches have been explored. Studies combining leptin with pramlintide (an amylin analogue) showed greater weight loss than either agent alone in clinical trials; however, this development programme was subsequently discontinued due to immunogenicity concerns and strategic decisions, and no licensed combination exists.

Another investigational direction involves using leptin to prevent weight regain after initial weight loss. Research has shown that falling leptin during caloric restriction triggers compensatory mechanisms promoting weight regain. Administering leptin to maintain pre-weight-loss concentrations may counteract some of these adaptations in research settings, though long-term efficacy, safety, and clinical applicability require further study.

Gene therapy approaches targeting leptin or its receptors remain largely experimental, with significant practical and ethical considerations limiting near-term clinical application.

For UK patients and healthcare professionals, these developments remain investigational and are not part of routine clinical practice. Participation in clinical trials through academic centres may offer access to novel leptin-based therapies for eligible individuals. To find UK clinical trials, visit the NIHR Be Part of Research website at bepartofresearch.nihr.ac.uk. Evidence-based, MHRA-approved treatments should remain the foundation of obesity management, with referral to specialist NHS weight management services and consideration of NICE-recommended pharmacotherapy or bariatric surgery where appropriate.

Frequently Asked Questions